Essilorluxottica (OTC) ((ESLOY)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Essilorluxottica is conducting a clinical study titled Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression. The study aims to evaluate the efficacy and safety of a new spectacle lens with passive red-light emission in controlling myopia progression in children aged 6 to 11. This research is significant as it explores innovative solutions to a growing global health concern.
The intervention involves testing two types of spectacle lenses: a standard single vision lens (SVL) and a myopia control lens (MCL), both designed with passive red-light emission. These lenses are intended to slow down the progression of myopia in children.
The study is designed as a 2-year, randomized, double-masked, parallel trial. Participants will wear different lenses in each eye, with lenses being switched after one year. The primary purpose is treatment, and both participants and investigators are masked to the lens types.
The study began on February 24, 2025, with primary completion expected by August 2025. The last update was submitted on August 4, 2025. These dates are crucial as they indicate the study’s progress and potential timelines for results.
The market implications of this study are notable. Success in this trial could enhance Essilorluxottica’s market position and positively influence its stock performance. It may also impact investor sentiment, particularly as the company competes in a market where innovative eye care solutions are in demand.
The study is ongoing, with further details available on the ClinicalTrials portal.